Ayala Pharmaceuticals Inc (ADXS)

[Swizzer13]

Repost of my message couple days ago:

PETX presented 2 slides on AT-014 at the Cantor Fitzgerald Conference. Here the text as copied from their presentation (dated September 27th):

SLIDE 28:

AT-014
Canine Osteosarcoma Vaccine
An investigational immunotherapeutic vaccine to target HER2-expressing canine
osteosarcoma licensed from Advaxis

? Preliminary data suggest AT-014 may be able to delay or prevent metastatic
disease and prolong overall survival in dogs with osteosarcoma that had
minimal residual disease following tumor removal
? Osteosarcoma is the most common primary bone tumor in dogs and
approximately 10,000 dogs a year are diagnosed in the U.S. (predominantly
middle to older-aged dogs and larger breeds)1
? Current standard of care treatment is amputation immediately after diagnosis,
followed by chemotherapy and sometimes radiation
? Aratana anticipates conditional licensure by the USDA in the second half of 2017
1. Small Animal Clinical Oncology (5th edition); Stephen Withrow, David Vail, Rodney Page; Elsevier 2013; page 463

SLIDE 29:

AT-014 Canine Osteosarcoma Vaccine
? AT-014 uses a live vector to access antigenpresenting cells
? The activated cells secrete TAA-fusion proteins and
may trigger innate, adaptive pathogen immune response
? As a result, the tumor cells are “seen” by the immune
system as pathogen-infected and are targeted by T-cells

Sorry if not easy to read, had to copy from a PDF with pictures. It is located on the PETX website (Investors - presentations)

So, at least Sept 27th things were ongoing and PETX submitted what they believe is required to get conditional licensure.